About
Tauopathies and Alzheimer’s disease
Areas of Focus
Categories
Small Molecule Pharmaceutical
Clinical Trials (5)
View allTotal Trials
5
As Lead Sponsor
4
As Collaborator
1
Total Enrollment
213
By Phase
PHASE2: 1PHASE1: 4
By Status
COMPLETED: 3TERMINATED: 2
Clinical Trials Pipeline5 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2020
2021
2022
2023
2024
2025
Today
Hover over trial bars to see details
Recent Trials
NCT06677203Lead Sponsor
Study of ASN51 in Adults With Early Alzheimer's Disease
PHASE2Terminated
123 participants
Started: Oct 16, 2024 · Completed: Nov 8, 2024
NCT06232109Lead Sponsor
Drug-Drug Interaction of ASN51 With Fluvoxamine, Itraconazole and Paroxetine in Healthy Subjects
PHASE1Completed
50 participants
Started: Feb 22, 2024 · Completed: Jul 3, 2024
NCT05725005Lead Sponsor
PET Study of Repeated ASN51 in Healthy Volunteers
PHASE1Completed
12 participants
Started: Jan 26, 2023 · Completed: Jun 8, 2023
NCT06390098Lead Sponsor
Positron Emission Tomography Study in Healthy Subjects to Determine the Relationship Between Plasma Concentration and Brain Target Occupancy of ASN51
PHASE1Completed
3 participants
Started: Aug 9, 2021 · Completed: Oct 12, 2021
NCT04759365Collaborator
Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Oral ASN51 in Healthy Subjects and Subjects With Alzheimer's Disease
PHASE1Terminated
25 participants
Started: Jun 2, 2021 · Completed: Aug 1, 2022
Locations (1)
Headquarters
Lausanne, Switzerland
Map
Loading map...